Interactions of human gut microbiome members with human-targeted pharmaceuticals – a single cell approach
Duration of contract: 4 years
Planned starting date: ASAP
Place of work: University of Vienna
Main supervisor: Michael Wagner (CV | Lab Homepage) and David Berry (CV | Lab Homepage)
Supervision team: Christine Moissl-Eichinger, Alexander Moschen
Project description:
This postdoc position will work together with other members of the work package to characterize changes in the composition and function of human gut (small and large intestine) microbial community members in response to widely used (combinations of) human-targeted pharmaceuticals. In addition to cutting-edge 16S rRNA gene amplicon sequencing and meta-omics techniques a focus will be on the application of single cell isotope probing techniques to quantify activity changes of microbial community members in response to pharmaceuticals as well as bioaccumulation of pharmaceuticals by gut microbes. For single cell activity measurements, heavy water stable isotope probing will be combined with fluorescence in situ hybridization and stimulated Raman spectroscopy (SRS) using an instrument that is unique in Europe. Bioaccumulation will be measured with NanoSIMS, SRS or mid-infrared photothermal spectroscopy. The results from incubation experiments with samples from healthy humans will be compared with microbiome data from respective patient cohorts.
The ideal candidate is interested in human gut microbiomes, has a background in microbiology and experience in molecular and microscopic tools for the characterization of microbial communities.
Links:
